Jackson Creek Investment Advisors LLC Makes New Investment in Guardian Pharmacy Services, Inc. $GRDN

Jackson Creek Investment Advisors LLC bought a new position in Guardian Pharmacy Services, Inc. (NYSE:GRDN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,578 shares of the company’s stock, valued at approximately $439,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. increased its stake in shares of Guardian Pharmacy Services by 26.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock valued at $43,000 after acquiring an additional 345 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Guardian Pharmacy Services during the 2nd quarter valued at about $43,000. State of Wyoming acquired a new position in shares of Guardian Pharmacy Services during the 2nd quarter valued at about $58,000. Strs Ohio acquired a new position in shares of Guardian Pharmacy Services during the 4th quarter valued at about $75,000. Finally, Clearstead Advisors LLC increased its stake in shares of Guardian Pharmacy Services by 196.3% during the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock valued at $79,000 after acquiring an additional 1,741 shares during the last quarter.

Guardian Pharmacy Services Trading Up 1.3%

GRDN opened at $39.11 on Thursday. The company has a fifty day simple moving average of $37.10 and a 200 day simple moving average of $33.15. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of 47.12, a PEG ratio of 2.53 and a beta of 0.09. Guardian Pharmacy Services, Inc. has a twelve month low of $19.17 and a twelve month high of $41.36.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. The business had revenue of $336.60 million during the quarter, compared to analyst estimates of $329.89 million. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The business’s revenue was up 2.2% on a year-over-year basis. During the same period last year, the business earned $0.22 EPS. On average, analysts forecast that Guardian Pharmacy Services, Inc. will post 1.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardian Pharmacy Services

In other Guardian Pharmacy Services news, Director John Ackerman sold 1,103,364 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $32,747,843.52. Following the sale, the director directly owned 345,123 shares in the company, valued at $10,243,250.64. The trade was a 76.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Fred Burke sold 671,432 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $19,928,101.76. Following the sale, the insider owned 840,413 shares in the company, valued at $24,943,457.84. This represents a 44.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 9,726,405 shares of company stock worth $288,679,700. 32.96% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GRDN. Zacks Research lowered Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Jefferies Financial Group began coverage on Guardian Pharmacy Services in a research report on Monday, March 30th. They issued a “buy” rating and a $44.00 target price on the stock. Weiss Ratings lowered Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Oppenheimer increased their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Finally, Truist Financial increased their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.